Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who ...

Sanofi Sees Progress for Hives Treatment in EU, Longer U.S. Review for MS Drug

France's Sanofi said its Dupixent drug jointly developed with Regeneron advanced toward a new indication for chronic hives in the European Union, while the U.S. Food and Drug Administration extended ...

Novartis Pharma AG: Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled dise ...

Novartis' skin disease drug gets US approval

The twice-daily pill, Rhapsido, is approved for patients with symptoms of chronic spontaneous urticaria (CSU) despite ...
Everyday Health on MSN

Chronic Idiopathic Urticaria Treatment: Medication, Lifestyle Changes, and More

Treatment for chronic hives lasting at least 6 weeks may include one or more types of medication, as well as certain lifestyle changes.

Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to ...

Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...
PharmiWeb

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIf approved, Dupixent would be the first ...
Mena FN

Global Chronic Idiopathic Urticaria Treatment Market Set For Significant Growth Through 2034

The Chronic Idiopathic Urticaria (CIU) Treatment Market is projected to grow from USD 1.5 bn in 2024 to USD 2.7 bn by 2034, reflecting a steady CAGR of 6.0%. VANCOUVER, BC, CANADA, September 10, 2025 ...

5 ways to treat fire ant bites, according to experts

Fire ant bites can sting multiple times. Here's what you need to know about treating those bites, according to health experts ...
Mena FN

Chronic Urticaria Or Hives Pipeline Analysis, 2025 By Delveinsight Novartis, Synermore Biologics, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Celltrion, United Biopharma ...

"Chronic Urticaria or Hives Pipeline Analysis"DelveInsight's,“Chronic Urticaria or Hives - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in ...
Everyday Health

What to Do When Antihistamines Stop Working for Chronic Hives: 4 Options

In many cases, over-the-counter antihistamines (also known as H1 antihistamines) tend to be enough to provide relief, says Nicole Weiler, MD, a dermatologist and clinical assistant professor of ...